UY37225A - Inhibidores del potenciador del homólogo zeste 2 campo de la invención - Google Patents
Inhibidores del potenciador del homólogo zeste 2 campo de la invenciónInfo
- Publication number
- UY37225A UY37225A UY0001037225A UY37225A UY37225A UY 37225 A UY37225 A UY 37225A UY 0001037225 A UY0001037225 A UY 0001037225A UY 37225 A UY37225 A UY 37225A UY 37225 A UY37225 A UY 37225A
- Authority
- UY
- Uruguay
- Prior art keywords
- zeste
- inhibitors
- homologist
- potentiator
- field
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Esta invención se refiere a nuevos compuestos de acuerdo con la Fórmula (I) que son inhibidores del Potenciador del Homólogo Zeste 2 (EZH2), a composiciones farmacéuticas que los contienen, a procedimientos para su preparación y a su uso en terapia para el tratamiento de cánceres.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332131P | 2016-05-05 | 2016-05-05 | |
US201662359904P | 2016-07-08 | 2016-07-08 | |
US201762454143P | 2017-02-03 | 2017-02-03 | |
US201762482964P | 2017-04-07 | 2017-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37225A true UY37225A (es) | 2017-11-30 |
Family
ID=58709513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037225A UY37225A (es) | 2016-05-05 | 2017-05-03 | Inhibidores del potenciador del homólogo zeste 2 campo de la invención |
Country Status (21)
Country | Link |
---|---|
US (1) | US10604531B2 (es) |
EP (1) | EP3452483B1 (es) |
JP (1) | JP2019516685A (es) |
KR (1) | KR20190003699A (es) |
CN (1) | CN109328188A (es) |
AU (1) | AU2017260854B2 (es) |
BR (1) | BR112018072740A2 (es) |
CA (1) | CA3023157A1 (es) |
CL (1) | CL2018003121A1 (es) |
CO (1) | CO2018011819A2 (es) |
CR (1) | CR20180521A (es) |
DO (1) | DOP2018000238A (es) |
ES (1) | ES2801423T3 (es) |
IL (1) | IL262701A (es) |
MX (1) | MX2018013519A (es) |
PE (1) | PE20190106A1 (es) |
PH (1) | PH12018502314A1 (es) |
SG (1) | SG11201809560QA (es) |
TW (1) | TW201806955A (es) |
UY (1) | UY37225A (es) |
WO (1) | WO2017191545A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
US20210000815A1 (en) * | 2017-12-28 | 2021-01-07 | Constellation Pharmaceuticals, Inc. | Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies |
CN112004816B (zh) | 2018-01-31 | 2024-01-05 | 米拉蒂医疗股份有限公司 | Prc2抑制剂 |
EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
CN111537654B (zh) * | 2020-07-07 | 2020-11-10 | 上海亚盛医药科技有限公司 | N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法 |
CN112830957B (zh) * | 2021-01-07 | 2022-07-22 | 江西师范大学 | 一种制备卡非佐米的方法 |
WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
DK1284740T3 (da) | 2000-05-19 | 2008-08-04 | Corixa Corp | Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser |
AU8100101A (en) | 2000-08-04 | 2002-02-18 | Corixa Corp | New immunoeffector compounds |
JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
WO2002074769A1 (fr) | 2001-03-19 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
CA2489004C (en) | 2002-06-13 | 2013-01-08 | Crucell Holland B.V. | Agonistic binding molecules to the human ox40 receptor |
ES2654064T3 (es) | 2002-07-03 | 2024-03-13 | Ono Pharmaceutical Co | Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1 |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
RU2549701C2 (ru) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
EP2851374B1 (en) | 2007-12-14 | 2017-05-03 | Bristol-Myers Squibb Company | Binding molecules to the human OX40 receptor |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
MX349463B (es) | 2008-09-26 | 2017-07-31 | Univ Emory | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
DK2609118T3 (en) | 2010-08-23 | 2017-04-03 | Univ Texas | Anti-OX40 antibodies and methods for their use |
BR112013025045B1 (pt) | 2011-03-31 | 2020-10-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | anticorpos direcionados contra icos e usos dos mesmos |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
CN103946238B (zh) | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
BR122022015975B1 (pt) | 2012-05-15 | 2024-01-02 | Bristol-Myers Squibb Company | Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
CA3139031A1 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
KR20160003115A (ko) | 2013-04-30 | 2016-01-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
EP3521285A1 (en) | 2014-06-17 | 2019-08-07 | Pfizer Inc | Substituted dihydroisoquinolinone compounds |
MA40848A (fr) * | 2014-10-28 | 2021-05-05 | Glaxosmithkline Ip No 2 Ltd | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) |
AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
-
2017
- 2017-05-01 WO PCT/IB2017/052523 patent/WO2017191545A1/en unknown
- 2017-05-01 MX MX2018013519A patent/MX2018013519A/es unknown
- 2017-05-01 SG SG11201809560QA patent/SG11201809560QA/en unknown
- 2017-05-01 CA CA3023157A patent/CA3023157A1/en not_active Abandoned
- 2017-05-01 ES ES17723766T patent/ES2801423T3/es active Active
- 2017-05-01 JP JP2018557862A patent/JP2019516685A/ja active Pending
- 2017-05-01 BR BR112018072740-7A patent/BR112018072740A2/pt not_active IP Right Cessation
- 2017-05-01 US US16/097,322 patent/US10604531B2/en not_active Expired - Fee Related
- 2017-05-01 CR CR20180521A patent/CR20180521A/es unknown
- 2017-05-01 PE PE2018002174A patent/PE20190106A1/es unknown
- 2017-05-01 EP EP17723766.6A patent/EP3452483B1/en active Active
- 2017-05-01 CN CN201780038943.5A patent/CN109328188A/zh active Pending
- 2017-05-01 KR KR1020187034784A patent/KR20190003699A/ko not_active Application Discontinuation
- 2017-05-01 AU AU2017260854A patent/AU2017260854B2/en not_active Ceased
- 2017-05-03 TW TW106114574A patent/TW201806955A/zh unknown
- 2017-05-03 UY UY0001037225A patent/UY37225A/es unknown
-
2018
- 2018-10-31 DO DO2018000238A patent/DOP2018000238A/es unknown
- 2018-10-31 CO CONC2018/0011819A patent/CO2018011819A2/es unknown
- 2018-10-31 IL IL262701A patent/IL262701A/en unknown
- 2018-10-31 CL CL2018003121A patent/CL2018003121A1/es unknown
- 2018-11-05 PH PH12018502314A patent/PH12018502314A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20190092785A1 (en) | 2019-03-28 |
MX2018013519A (es) | 2019-03-14 |
IL262701A (en) | 2018-12-31 |
CN109328188A (zh) | 2019-02-12 |
CA3023157A1 (en) | 2017-11-09 |
CL2018003121A1 (es) | 2018-12-14 |
US10604531B2 (en) | 2020-03-31 |
SG11201809560QA (en) | 2018-11-29 |
KR20190003699A (ko) | 2019-01-09 |
AU2017260854B2 (en) | 2020-01-30 |
CO2018011819A2 (es) | 2018-11-22 |
JP2019516685A (ja) | 2019-06-20 |
PH12018502314A1 (en) | 2019-04-15 |
TW201806955A (zh) | 2018-03-01 |
EP3452483A1 (en) | 2019-03-13 |
DOP2018000238A (es) | 2019-10-31 |
AU2017260854A1 (en) | 2018-11-15 |
PE20190106A1 (es) | 2019-01-15 |
BR112018072740A2 (pt) | 2019-02-19 |
WO2017191545A1 (en) | 2017-11-09 |
EP3452483B1 (en) | 2020-04-01 |
ES2801423T3 (es) | 2021-01-11 |
CR20180521A (es) | 2019-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CO2022010241A2 (es) | Inhibidores de sos1 | |
UY37225A (es) | Inhibidores del potenciador del homólogo zeste 2 campo de la invención | |
UY37870A (es) | Inhibidores de kras g12c y métodos para utilizarlos campo de la invención | |
CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
CO2021003036A2 (es) | Compuestos de anillo fusionado | |
CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2019002461A1 (es) | Arn terapéutico. | |
NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
CO2017011183A2 (es) | Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación | |
UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
CL2016003350A1 (es) | Inhibidores de demetilasa-1 especifica de lisina | |
EA201890052A1 (ru) | Регуляторы nrf2 | |
DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
BR112017008840A2 (pt) | intensificador de inibidores do homólogo 2 de zeste | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
ECSP17023551A (es) | Inhibidores de histona desmetilasa | |
CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
EA201790604A1 (ru) | Ингибиторы гистондеметилазы | |
ECSP18056196A (es) | Derivados de indano | |
CO2021014351A2 (es) | Derivados de quinolina y su uso para el tratamiento del cáncer |